EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Hisse Analizi

EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Sağlık ve Boru Hattı Genel Bakışı

EPIRUS Biopharmaceuticals aimed to revolutionize treatment for inflammatory diseases and ultra-rare blood disorders through biosimilar development, offering potential cost-effective alternatives, before filing for Chapter 7 liquidation in 2016, ceasing operations and development.

Yatırım Tezi

Investing in EPRSQ is not advisable due to the company's Chapter 7 liquidation filing in 2016. The company's assets are being liquidated, and there is no ongoing business operation. The potential for return on investment is extremely low. The company's pipeline of biosimilar product candidates, including BOW015, BOW050, BOW070, BOW080, and BOW100, are no longer under development. The company's market capitalization is effectively zero, reflecting its defunct status. Investors should be aware of the high risk associated with investing in companies undergoing liquidation.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

• Lead product candidate BOW015 was a biosimilar version of Remicade (infliximab) targeting inflammatory diseases.
• Pipeline included biosimilars for Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI.
• Collaborations with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
• Filed for Chapter 7 liquidation on July 25, 2016.
• Market capitalization is $0.00B, reflecting its defunct status.

Rakipler & Benzerleri

Güçlü Yönler

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

Zayıflıklar

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

Katalizörler

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

Riskler

• Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.
• Ongoing: No ongoing business operations.
• Ongoing: No potential for future revenue generation.

Büyüme Fırsatları

• Growth opportunity 1: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
• Growth opportunity 2: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
• Growth opportunity 3: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
• Growth opportunity 4: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
• Growth opportunity 5: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.

Fırsatlar

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

Tehditler

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.

Rekabet Avantajları

• Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no competitive advantages associated with the company.

EPRSQ Hakkında

Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company dedicated to developing, manufacturing, and commercializing biosimilar therapeutics on a global scale. The company's core strategy revolved around creating biosimilar versions of established biologic drugs, offering potentially more affordable treatment options for a range of diseases. Their lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), targeting inflammatory diseases. The pipeline also included BOW050, a biosimilar of Humira (adalimumab); BOW070, a biosimilar of Actemra (tocilizumab); BOW080, a biosimilar of Soliris; and BOW100, a biosimilar of SIMPONI. These biosimilars were intended to treat a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, and ultra-rare blood disorders. EPIRUS established strategic collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, EPIRUS Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court, effectively halting its operations and development programs.

Ne Yaparlar

• Developed biosimilar therapeutics.
• Aimed to manufacture biosimilar versions of existing biologic drugs.
• Focused on treatments for inflammatory diseases and ultra-rare blood disorders.
• Sought to commercialize biosimilars globally.
• Partnered with other pharmaceutical companies for development and distribution.
• Filed for Chapter 7 liquidation in 2016.

İş Modeli

• Develop biosimilar versions of branded biologic drugs.
• Out-license or co-develop biosimilars with partners.
• Commercialize biosimilars directly or through partners.
• Generate revenue through product sales and licensing fees.

Sektör Bağlamı

The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like ALNAQ, ARTH, GNRS, GWHP, and INTP operate in this space. The biosimilar market offers opportunities for companies to develop and commercialize cost-effective alternatives to existing biologic drugs. However, the industry also faces challenges such as patent disputes, regulatory hurdles, and pricing pressures. EPIRUS Biopharmaceuticals aimed to capitalize on the biosimilar market but ultimately failed due to financial constraints, leading to its liquidation.

Kilit Müşteriler

• Patients suffering from inflammatory diseases.
• Healthcare providers prescribing biologic drugs.
• Hospitals and clinics using biologic treatments.
• Pharmaceutical companies partnering for distribution.

Finansallar

Grafik & Bilgi

Son Haberler

EPRSQ için son haber bulunmamaktadır.

Analist Konsensüsü

MoonshotScore

Yatırımcılar EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Hakkında Ne Soruyor

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Popüler Hisseler